24/7 Market News Snapshot 16 April, 2025 – Redhill Biopharma Ltd. (NASDAQ:RDHL)

April 16, 2025

DENVER, Colo., 16 April, 2025 (www.247marketnews.com) – (NASDAQ:RDHL) are discussed in this article.
Redhill Biopharma Ltd. is demonstrating notable momentum in the financial markets alongside innovative advancements in therapeutics. Recently, the company’s stock, trading under the symbol RDHL, soared by 21.73% in pre-market activity, reaching a price of $2.599. This significant surge from the previous session’s close of $2.135 reflects heightened investor enthusiasm, with a trading volume of approximately 1.50 million shares. The robust market interest signals strong potential for continued growth, aligning with the company’s strategic initiatives designed to foster innovation and enhance shareholder value.

In addition to this impressive trading activity, Redhill has announced promising preclinical results for Opaganib, a novel oral treatment aimed at obesity and diabetes. Published in the journal Diabetes, Metabolic Syndrome and Obesity, the study highlights Opaganib’s efficacy in promoting weight loss and improving metabolic markers, demonstrating performance comparable to established GLP-1 inhibitors like semaglutide. As a first-in-class sphingosine kinase-2 selective inhibitor, Opaganib targets a range of signaling pathways, potentially reducing the common side effects associated with traditional GLP-1 therapies.

Dr. Mark Levitt, Chief Scientific Officer of Redhill, noted the implications of these findings, emphasizing Opaganib’s ability to address the growing obesity and diabetes epidemic effectively. Preliminary results from studies involving high-fat diets revealed that Opaganib successfully suppressed weight gain and enhanced glucose tolerance in animal models, positioning it as a promising candidate for the treatment of obesity-related disorders.

With a projected drug market for obesity and diabetes reaching $100 billion by 2034, Redhill’s initiatives are not only timely but crucial. The firm is focused on expediting the FDA approval process for Opaganib, highlighting its commitment to addressing critical health challenges while diversifying its therapeutic portfolio across multiple indications, including oncology and infectious diseases. As Redhill Biopharma continues to advance its objectives, both investors and patients alike are poised to benefit from its innovative solutions.

Related news for (RDHL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.